Study summary · research use only
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This article discusses application of afamelanotide, an alpha-melanocyte-stimulating hormone agonistic analogue, in erythropoietic protoporphyria, a disease with sunlight intolerance. The abstract describes the clinics, genetics and existing therapies of protoporphyria, the receptor-mediated signaling of alpha-melanocyte stimulating hormone, and the pharmacological action and rationale for afamelanotide. It states results of several Phase II and III trials and safety issues are discussed, that trial results were significant though not large in absolute terms, and that a favorable risk-safety profile and high compliance during six years of a compassionate-use program in Switzerland led the authors to anticipate afamelanotide and analogues becoming a therapeutic tool, hoping for child-suitable dosage forms.
Abstract
The application of afamelanotide, an α-melanocyte stimulating hormone agonistic analogue to protoporphyria, a disease with absolute sunlight-intolerance is discussed. The clinics, genetics and existing therapies of protoporphyria are described. The physiological receptor-mediated intracellular signaling of α-melanocyte stimulating hormone and effects of receptor variants are outlined. The pharmacological action of afamelanotide and the rationale behind its application in protoporphyria are given. The results of several Phase II and III and safety issues are discussed. The trial results were significant, although the effects were not very large in absolute terms, and the risk-safety profile is favorable today. Based on the high compliance rate and the excellent consistency in clinical effectiveness during six years of compassionate use program in Switzerland, we expect afamelanotide and analogues to become a prospective therapeutic tool. Moreover, we hope that dosage forms suitable for children will be developed in future, as children and adolescents suffer most in protoporphyria.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.